Nanoviricides (NNVC) Capital Expenditures (2010 - 2026)
Nanoviricides (NNVC) posted Capital Expenditures of $85029.0 for Q1 2026, up 24051.83% sequentially from -$355.0 in Q4 2025.
Nanoviricides (NNVC) Capital Expenditures (2010 - 2026) Analysis & Trends
Nanoviricides has reported Capital Expenditures for 16 years, with the latest figure at $85029.0 in Q1 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $85029.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25435.0 (down 87.2% YoY) and the FY2025 annual result came in at -$12117.0, down 107.74% from the prior year.
- Capital Expenditures rose to $85029.0 in Q1 2026 per NNVC's latest filing, from -$355.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $248986.0 in Q1 2022 and troughed at -$58881.0 in Q2 2025.
- A 5-year average of $32814.2 and a median of -$356.5 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures jumped 10749.53% in 2022, then plunged 11816.22% in 2024.
- Over 5 years, Capital Expenditures stood at -$9078.0 in 2022, then soared by 252.04% to $13802.0 in 2023, then surged by 270.77% to $51173.0 in 2024, then slumped by 100.69% to -$355.0 in 2025, then surged by 24051.83% to $85029.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $85029.0, -$355.0, and -$358.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 251.02 Mn |
| 10 | Nanoviricides | 29.50 Mn | 26.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85,029.00 |
| Mar 31, 2026 | 85,029.00 |
| Dec 31, 2025 | -355.00 |
| Dec 31, 2025 | -355.00 |
| Sep 30, 2025 | -358.00 |
| Sep 30, 2025 | -358.00 |
| Jun 30, 2025 | -58,881.00 |
| Jun 30, 2025 | -58,881.00 |
| Dec 31, 2024 | 51,173.00 |
| Dec 31, 2024 | 51,173.00 |
| Sep 30, 2024 | -4,409.00 |
| Sep 30, 2024 | -4,409.00 |
| Jun 30, 2024 | 152,013.00 |
| Jun 30, 2024 | 152,013.00 |
| Mar 31, 2024 | -9,218.00 |
| Mar 31, 2024 | -9,218.00 |
| Dec 31, 2023 | 13,802.00 |
| Dec 31, 2023 | 13,802.00 |
| Sep 30, 2023 | -37.00 |
| Sep 30, 2023 | -37.00 |